Crohn's disease Treatment Market Share

Geographically, the crohn's disease treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa region. The market in the Asia Pacific industry is poised to account for largest revenue share by 2036, owing to increasing awareness about Crohn’s disease, and need to develop innovative inflammatory bowel disease treatment solutions in the region. Increasing R&D of biosimilars for the treatment of Crohn’s disease is expected to boost growth of the market in the Asia Pacific. In 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the R&D of novel biosimilars and drugs for the Crohn’s disease treatment. For instance, in August 2016, the U.S. Food and Drug Administration (FDA) approved two biosimilars Amjevita and Erelzi, manufactured by Amgen to treat inflammatory bowel disease.